中文名称: | DMHCA | ||||
---|---|---|---|---|---|
英文名称: | DMHCA | ||||
别名: | DMHCA 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+) | ||||
CAS No: | 79066-03-8 | 分子式: | C26H43NO2 | 分子量: | 401.63 |
CAS No: | 79066-03-8 | ||||
分子式: | C26H43NO2 | ||||
分子量: | 401.63 |
基本信息
产品编号: |
D70152 |
||||
产品名称: |
DMHCA |
||||
CAS: |
79066-03-8 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
六个月 |
||
分子量 |
401.63 |
-20℃ |
一个月 |
||
化学名: |
3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+) |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
7mg/mL(17.429mM;Need ultrasonic) |
|||
Ethanol |
|
||||
Water |
|
||||
体内(现配现用): |
1.请依序添加每种溶剂:10% DMSO→90% (20% SBE-β-CD in saline) Solubility:≥0.77mg/mL(1.92mM);Clear solution |
||||
此⽅案可获得≥0.77mg/mL(1.92mM,饱和度未知)的澄清溶液。以1mL⼯作液为例,取100μL7.7mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中,混合均匀。 |
|||||
2.请依序添加每种溶剂:10% DMSO→90% corn oil Solubility:≥0.77mg/mL(1.92mM);Clear solution |
|||||
此⽅案可获得≥0.77mg/mL(1.92mM,饱和度未知)的澄清溶液,此⽅案不适⽤于实验周期在半个⽉以上的实验。以1mL⼯作液为例,取100μL7.7mg/mL的澄清DMSO储备液加到900μL⽟⽶油中,混合均匀。 |
|||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.4899mL |
12.4493mL |
24.8985mL |
5mM |
0.4980mL |
2.4899mL |
4.9797mL |
10mM |
0.2490mL |
1.2449mL |
2.4899mL |
生物活性
产品描述 |
一种有效的选择性LXR激动剂,特别激活LXR通路的胆固醇流出臂,而不刺激甘油三酯的合成。DMHCA具有抗炎作用,可用于糖尿病胆固醇稳态的研究。 |
靶点 |
IC50: LXR |
体外研究 |
In ex vivo treatment of diabetic CD34+ cells, DMHCA (10 µM; 16-18 hours) restores the fluidity of the membranes to baseline nondiabetic levels. DMHCA restores the levels of BM-derived TNF-α and IL-3 to baseline and significantly reduces CCL-2 production by >50% in the BM supernatants and the systemic circulation compares to the control mice. DMHCA also increases the number of CACs in the BM and peripheral circulation and upregulates the egression of vascular reparative cells into the peripheral circulation . In the PAGA analysis, DMHCA treatment enhances the overall production and robustness of erythrocyte progenitors. DMHCA enhances flux down the erythrocyte progenitor lineage. It also DMHCA increase in erythrocyte progenitor density in BM cells. DMHCA not only expands the proportion of erythrocyte progenitors but also increases the expression of the hemoglobin beta adult chain (HBB-BT) |
体内研究 |
DMHCA (oral administration; 6 months; chow 8mg/kg body weight /day) restores cholesterol homeostasis in diabetic retina. It significantly increases endogenous LXR ligands, desmosterol, and total oxysterols in the diabetic retina |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )